IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1541 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  Next article
  Previous article 
  Table of Contents
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (63 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   Conclusion:
   References

 Article Access Statistics
    Viewed3155    
    Printed153    
    Emailed4    
    PDF Downloaded218    
    Comments [Add]    

Recommend this journal

 
MOLECULES OF THE MILLENNIUM
Year : 2004  |  Volume : 36  |  Issue : 3  |  Page : 189
 

Bevacizumab


Department of Pharmacology, Himalyan Institute of Medical Sciences, Dehradun - 248140, India

Correspondence Address:
Department of Pharmacology, Himalyan Institute of Medical Sciences, Dehradun - 248140, India
anu1407@rediffmail.com



How to cite this article:
Nischal A, Dhasmana D C. Bevacizumab. Indian J Pharmacol 2004;36:189


How to cite this URL:
Nischal A, Dhasmana D C. Bevacizumab. Indian J Pharmacol [serial online] 2004 [cited 2019 Aug 23];36:189. Available from: http://www.ijp-online.com/text.asp?2004/36/3/189/6884


Revolutionary changes are on cards with immuno modulatory approaches for various tumours with solid understanding of molecular cancer biology. Such agents may be synergistic or additive to the standard cancer chemotherapy, radiotherapy or with surgery as adjuvant or as neoadjuvant chemotherapy. One such agent in this category is bevacizumab, a humanized monoclonal antibody targeted against circulatory proangiogenic vascular endothelial growth factor (VEGF). It stops tumours from making new blood vessels, an obligatory step specially for survival and growth of various solid tumours.
Mechanism of action: Tumour growth beyond a few cubic millimeters cannot occur without the nutritional support of induced new blood vessels called angiogenesis. Angiogenesis promotes this support essentially in solid tumour growth and metastasis. This process as such is tightly regulated depending upon the complex interplay of inhibitory and stimulatory angiogenic factors. VEGF is one of the best characterized pro angiogenic growth factor the effect of which are mediated by VEGF-1 and VEGF-2 receptors expressed on vascular endothelium. VEGF binds with VEGF receptors and promotes endothelial cell migration and proliferation, the two foremost essential steps in the development of new blood vessels. VEGF also increases vascular permeability whereby contributing further angiogenesis and tumour growth. It is expressed substantially in tumour cells and the expression is correlated with chemotherapeutic resistance and poor prognosis in cancers. Thus bevacizumab acts by binding to VEGF thereby prevents triggering of blood vessel growth with subsequent inhibition of tumour growth and metastasis.
Therapeutic uses: Clinical phase II trials of bevacizumab as part of adjuvant therapy showed positive results in median progression free survival in untreated and metastasized colorectal cancer and renal cell carcinoma; the cancers in which chemotherapy is not of much significance. It is also being evaluated for other tumours i.e. metastatic breast cancer using variety of tumour treatment plans in terms of the dose, length of infusion, frequency of infusion and number of such treatments. It is also being evaluated in phase I/II clinical trials for other solid tumours i.e. previously treated metastatic breast carcinoma and others.
Phase II trials that are being conducted include carcinoma prostate, carcinoma cervix, carcinoma ovaries, pancreatic and lung carcinoma for its potential use in these cancers. It is also being studied for gastrointestinal stromal cell tumours, malignant mesotheliomas, AML, and myelodysplastic syndromes. Potential non-cancerous uses may be possible where angiogenesis is of disadvantage i.e. age related macular degeneration and others.
Dose: Bevacizumab is being studied using varied treatment plans in the dose range of 3-20 mg/kg, i.v. with varied length of infusions frequency of infusions and number of treatment cycles. Escalating doses of bevacizumab ranging from 3 -20 mg/kg, body weight every other week have been used in different types of tumours.10 mg/kg, body weight administered as an i.v. bolus injection every other week seemed to be the optimal dose with acceptable levels of tolerability.
Side effects: The limited experience with various clinical trials until now found that it is well tolerated by most patients. Serious life threatening adverse events such as thromboembolic episodes and bleeding have also been observed and few patients have experienced other adverse effects of concern i.e. hypertension, proteinuria, epistaxis, fever, headache, rash and chills. Perforation of the wall of the colon has also been observed in one patient.

  Conclusion: Top

While the evidence of antitumour activity over a broad spectrum of experimental tumours is clear, the proper selection, dose, timing and sequence of antiVEGF treatment in human cancers is not all obvious. Bevacizumab might prove to be a valuable addition to the existing armamentarium of drugs against cancer, incorporation of which in cytotoxic regimens may increase overall response rates. It may also prove to be effective in other conditions characterized by pathological angiogenesis.
 

  References Top

1.Gill S, Thomas RR, Goldberg RM. New targeted therapies in gastrointestinal cancers. Curr Treat Options Oncol 2003;4:393-403.  Back to cited text no. 1  [PUBMED]  
2.O'Neil BH, Goldberg RM. Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived. Expert Opin Investig Drugs 2003;12:1939-49.  Back to cited text no. 2    
3.Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003;3:263-76.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-4.  Back to cited text no. 4    
Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow